Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
NEW YORK, Feb. 17, 2016 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its fourth quarter and full year 2015 financial results prior to the NASDAQ market open on Tuesday, February 23, 2016. Intercept management will conduct a conference call and audio webcast on Tuesday, February 23, 2016 at 8:00 a.m. Eastern Time to discuss these results.
Intercept management will also be presenting at the following investor conference:
- Cowen 36th Annual Health Care Conference on Monday, March 7, 2016 at 1:20 p.m. Eastern Time
Webcast information for these events will be available on Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic non-viral, progressive liver diseases. The Company's lead product candidate, obeticholic acid (OCA), is an farnesoid X receptor (FXR) agonist. OCA is being developed to treat a variety of chronic liver diseases, including primary biliary cirrhosis, renamed primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. The FDA has granted OCA breakthrough therapy designation for the treatment of NASH with liver fibrosis and granted OCA fast track designation for the treatment of patients with PBC. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma. Intercept's pipeline of product candidates includes other novel bile acid analogs such as INT-767, which is in clinical development. For more information about Intercept, please visit the Company's website at: www.interceptpharma.com.
CONTACT: For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
